UNSPSC 51283906: Sulfabenzamide

This classification denotes a sulfonamide anti-infective agent with the molecular formula C13H12N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G58F8OPL4I, chemically known as sulfanilamide, n(sup1)-benzoyl- but generally known as sulfabenzamide, which bears US NIH Compound Identifier 5319. European Medicines Agency schedules Sulfabenzamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10684MIG.

UNSPSC 51283906 Sulfabenzamide, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The code nominally covers a specific sulfonamide pharmaceutical, yet the recent opportunities tagged under it—naloxone distribution, direct-to-manufacturer prescription programs, first-aid medical supplies, and generic pharmaceuticals procurement—do not involve sulfabenzamide itself. State and local buyers are instead sourcing diverse pharmaceutical products, OTC items, emergency medical consumables, and pharmacy benefit services through cooperative purchasing arrangements and health department procurement channels.

Recent activity spans Florida county health departments, Texas state health agencies, Florida municipal fire departments, and multi-state cooperative purchasing alliances. The City of Tampa is soliciting 169 line items of medical and emergency supplies for its Fire Department Rescue Division through an IFB (due March 13, 2026) with an estimated contract value of $700,000 and a sheltered-market 5% Small Local Business Enterprise bid discount; Seminole County, Florida is seeking naloxone and drug deactivation systems through competitive bidding (due July 26, 2023); the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting generic multi-source pharmaceuticals and OTC products through an RFP (due March 26, 2026) for distribution across state and local facilities; and the Texas Health and Human Services Commission issued an RFI (due April 3, 2026) to explore direct-to-manufacturer prescription contracting. The code shows activity concentrated in Florida and the upper Midwest multi-state cooperative environment, but the absence of sulfabenzamide-specific procurement in these recent solicitations suggests the code may be misapplied to broader pharmaceutical and medical supply categories within state and local procurement systems.